Zymeworks reports $455M cash, runway into 2H 2027; zanidatamab Phase 3 data expected 2024

Zymeworks Inc.

Preliminary unaudited cash resources of $455M as of Dec 31, 2023; expected funding into second half of 2027.
Top-line data from Phase 3 HERIZON-GEA-01 trial for zanidatamab in first-line HER2+ GEA expected in 2024.
Regulatory reviews ongoing in 2024 for zanidatamab in second-line BTC in US and China with Jazz and BeiGene.
IND filings planned for ZW171 and ZW191 in 2024; ZW220 and ZW251 in 2025; R&D Day in Q4 2024.
Completed $50M private placement with EcoR1 Capital, contributing to extended cash runway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.